View Older Stories View More Recent Stories

Sep 22, 2022 07:00AM Rivus Pharmaceuticals Closes $132 Million Series B Financing to Advance HU6 for the Treatment of Obesity and Cardio-Metabolic Disorders

Sep 21, 2022 08:31AM Latham BioPharm Group Announces Publication of Team Member's Paper in Leading Scientific Journal

Sep 16, 2022 04:30PM Form SC 13D/A POINT Biopharma Global Filed by: RA CAPITAL MANAGEMENT, L.P.

Sep 14, 2022 09:00AM GentiBio To Present Preclinical Data Demonstrating Technical Progress to Engineer Regulatory T Cells for the Prevention and Treatment of Autoimmune Diseases

Sep 12, 2022 07:00AM Nimbus Therapeutics Closes $125M Private Financing to Advance Clinical Programs in Autoimmune Diseases and Oncology

Sep 6, 2022 04:50PM Form SC 13D/A Solid Biosciences Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Sep 6, 2022 04:31PM Form SC 13G Cogent Biosciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Sep 2, 2022 04:30PM Form SC 13D/A Forma Therapeutics Holdi Filed by: RA CAPITAL MANAGEMENT, L.P.

Sep 1, 2022 08:01AM Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders

Sep 1, 2022 08:01AM Forma Therapeutics (FMTX) Acquired by Novo Nordisk for $20/sh or $1.1B

Sep 1, 2022 08:00AM Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders

Aug 29, 2022 05:02PM Form SC 13D/A POINT Biopharma Global Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 26, 2022 04:39PM Form SC 13G Fulcrum Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 22, 2022 08:30AM Ocelot Bio Receives FDA Orphan Drug Designation for OCE-205 for the Treatment of Hepatorenal Syndrome

Aug 22, 2022 07:00AM Concert Pharmaceuticals Announces Exercise of Warrants Under Existing Financing Arrangement

Aug 15, 2022 05:24PM Form 13F-HR RA CAPITAL MANAGEMENT, For: Jun 30

Aug 15, 2022 05:20PM Form SC 13G/A scPharmaceuticals Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 15, 2022 05:15PM Form SC 13G/A MACROGENICS INC Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 15, 2022 05:13PM Form SC 13G/A KalVista Pharmaceuticals Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 15, 2022 05:11PM Form SC 13G/A TScan Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 15, 2022 05:07PM Form SC 13G/A Cyteir Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 15, 2022 05:04PM Form SC 13G/A Akouos, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 15, 2022 05:00PM Form SC 13G/A Edgewise Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 12, 2022 04:34PM Form SC 13D/A Werewolf Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 11, 2022 04:00PM Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 10, 2022 07:00AM GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel Diseases

Aug 4, 2022 07:00AM Concert Pharmaceuticals Reports Second Quarter 2022 Financial Results

Jul 26, 2022 10:00AM Scribe Therapeutics Announces Expansion of San Francisco Bay Area Headquarters, 3 Key Senior Hires

Jul 26, 2022 07:00AM Carmot Therapeutics closes $160 million Series D financing to advance clinical pipeline of novel incretin receptor modulators

Jul 25, 2022 08:03AM NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation (FLAC) Announce Merger Agreement

Jul 25, 2022 08:00AM NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation Announce Merger Agreement to Create Publicly Listed Company Focused on Transformative Oral Therapies for Major Cardiom

Jul 20, 2022 08:00AM Medical Microinstruments Secures $75M to Advance Robotic Microsurgery

Jul 15, 2022 10:00AM Scribe Therapeutics to Participate in SVB Securities Biopharma Private Company Connect

Jul 13, 2022 05:45AM Hemab Therapeutics Presents New Data on HMB-001 for the Treatment of Glanzmann Thrombasthenia and Other Bleeding Disorders at 2022 ISTH Congress

Jul 12, 2022 08:15AM NAPIGEN Completes $7.85 Million Funding Round to Advance Its Mitochondrial and Chloroplast Gene Editing Technology

Jul 6, 2022 05:25PM Form SC 13D/A 89bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Jul 5, 2022 08:00AM 89bio Announces Closing of its Upsized $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

Jun 28, 2022 09:05AM Cerebral Therapeutics, Inc. Secures $40 Million Series C Financing

Jun 28, 2022 08:00AM Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard® in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (S

Jun 28, 2022 07:30AM DTx Pharma Appoints Peter Condon as Chief Business Officer

Jun 23, 2022 04:50PM Form SC 13D/A PepGen Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Jun 22, 2022 04:32PM Form SC 13G Instil Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Jun 21, 2022 04:36PM Form SC 13D/A Wave Life Sciences Ltd. Filed by: RA CAPITAL MANAGEMENT, L.P.

Jun 15, 2022 08:00AM Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer

Jun 14, 2022 09:00AM WAVE Life Sciences (WVE) Announces Pricing of $70.0 Million Underwritten Offering

Jun 14, 2022 09:00AM Wave Life Sciences Announces Pricing of $70.0 Million Underwritten Offering

Jun 14, 2022 09:00AM Wave Life Sciences Announces Pricing of $70.0 Million Underwritten Offering

Jun 9, 2022 02:55AM DBV Technologies Announces Private Placement Financing of $194 Million

Jun 9, 2022 02:55AM DBV Technologies Announces Private Placement Financing of $194 Million

Jun 8, 2022 08:00AM Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension

View More Recent Stories View Older Stories